SP 102

Drug Profile

SP 102

Alternative Names: SP-102

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Semnur Pharmaceuticals
  • Class Steroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Back pain

Most Recent Events

  • 22 Nov 2016 Adverse events and pharmacokinetics data from preclinical trials in Pain released by Scintilla Pharmaceuticals (Scintilla Pharmaceuticals Presentation, September 2016)
  • 30 Sep 2016 Scintilla Pharmaceuticals announces intention to submit IND to FDA for Back Pain in first quarter of 2017 (Scintilla Pharmaceuticals Presentation, September 2016)
  • 15 Aug 2016 Phase-I/II trials in Back Pain in USA (Epidural) (9201638; Scintilla Pharmaceuticals Presentation, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top